NMDA Receptor Modulation for the Treatment of Bipolar I Disorder | MicrobiomeTrials← Back to trialsNCT05977023
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-10-04Est. Completion: 2027-11
Enrollment target: 90 participants Locations- Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan
Other microbiome trials you might be interested in
Bipolar Disorder Type I With Mania
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mani…
Glendale, United StatesEst. completion Jun 13, 2028
Bipolar 1 Disorder
This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. Th…
Little Rock, United StatesCompleted Aug 5, 2026